(QURE) uniQure N.V. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(QURE) uniQure N.V. Complete Analysis Pack
uniQure VRIO Analysis: Spot Durable Advantages Fast
Unlock uniQure N.V.’s strategic edge with the full VRIO Analysis—an actionable, company-specific file that reveals which resources create real, durable advantages and which are temporary or easily imitated; ideal for investors, analysts, consultants, and executives seeking clear, ready-to-use insights in Word and Excel.
. Lead hemophilia B gene therapy asset and Phase III evidence
Value
AMT-061, now etranacogene dezaparvovec, sits in hemophilia B, a rare U.S. market with about 1 in 25,000 male births and a one-time Hemgenix list price of $3.5 million. In HOPE-B, uniQure reported a 64% lower annualized bleed rate and 94% less factor IX use, which supports high value if durability holds.
Rarity
Hemophilia B gene therapy is rare: only a small group of Company Name peers have deep AAV engineering skills, and uniQure N.V. has one of the few late-stage platforms here. Its Phase III HOPE-B trial enrolled 54 patients, giving the asset scarce clinical proof in a very small field.
Imitability
UniQure N.V.'s hemophilia B gene therapy is hard to copy because it combines a liver-targeted AAV vector, the FIX-Padua transgene, and slow-to-build CMC and trial know-how. In Phase III HOPE-B, 54 patients were treated, and factor IX activity stayed in the normal-to-mild range while bleed rates fell sharply, making imitation costly and slow.
Organization
uniQure N.V. is organized around specialized clinical operations and tight regulatory planning, which fits a lead gene-therapy asset that needs complex trial execution and long follow-up. Its hemophilia B program was backed by the 54-patient Phase III HOPE-B study, which showed durable factor IX expression and a strong bleed reduction signal over 2 years.
Competitive Advantage
uniQure N.V.'s lead hemophilia B asset, etranacogene dezaparvovec (Hemgenix), has Phase III HOPE-B data that support a durable edge: mean annualized bleeding rate fell 64% from lead-in through month 24, and 96% of treated patients stayed off routine factor IX prophylaxis. That makes the claim harder to copy, because the one-time gene therapy and its long follow-up data create barriers rivals still lack.
Hemgenix Gives uniQure a Rare, Hard-to-Copy Hemophilia B Moat
Etranacogene dezaparvovec, marketed as Hemgenix, gives uniQure N.V. a rare gene-therapy moat in hemophilia B. In HOPE-B, 54 patients were treated and mean annualized bleeding rate fell 64% through month 24, with 96% off routine factor IX prophylaxis, making the asset hard to copy.
| Data point | Value |
|---|---|
| Asset | Hemgenix |
| Phase III | HOPE-B, 54 patients |
| Outcome | 64% lower bleeding rate |
| Prophylaxis-free | 96% |
What is included in the product
Detailed Word Document
A concise VRIO analysis of uniQure N.V.’s key resources, showing which capabilities are valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly reveals uniQure’s strategic resources, competitive edge, and defensibility without building a VRIO from scratch.
Reference Sources
Shows which uniQure resources are valuable, rare, hard to imitate, and organizationally supported to verify real competitive advantage.
. AAV gene therapy platform and vector-engineering know-how
Value
AMT-061/etranacogene dezaparvovec showed uniQure can build a high-value AAV platform: Hemgenix launched in 2022 as the first one-time gene therapy for hemophilia B, with a U.S. list price of $3.5 million. That one-dose model targets a rare, chronic orphan market where lifetime prophylaxis can cost millions, so the pricing power is real.
Rarity
uniQure N.V. is rare here because only a small set of firms can design AAV capsids, tune payload fit, and run the process end to end. By 2025, just a handful of AAV gene therapies had reached approval in major markets, so this depth of vector-engineering know-how is still hard to copy.
Imitability
Imitability is low because uniQure N.V. has spent years building AAV delivery, capsid engineering, and CMC know-how that is hard to copy fast. The moat is reinforced by its growing clinical base: as of 2025, it had multiple AAV programs in or near the clinic, and each new trial adds data, not just IP, which slows rivals and raises the bar on execution.
Organization
uniQure’s organization is built to support its AAV gene therapy platform, with specialized clinical operations and regulatory planning tied to late-stage programs like AMT-130 and HEMGENIX. That setup helps turn vector-engineering know-how into execution, which is hard for most biotechs to copy.
Competitive Advantage
uniQure N.V.'s AAV platform is a rare sustained edge because its vector-engineering know-how is protected by patents, trade secrets, and know-how tied to clinical manufacturing; that makes the claim hard to copy and legally enforceable. The company has advanced multiple AAV programs, including HEMGENIX, which won FDA approval in 2022 and was the first one-time gene therapy for hemophilia B, showing the platform’s real-world value.
uniQure’s AAV edge is hard to copy
uniQure N.V. has a real AAV edge: Hemgenix became the first one-time hemophilia B gene therapy in 2022, and by 2025 the company still had multiple AAV programs in the clinic. That mix of approved product, vector-engineering know-how, and CMC depth makes the platform hard to copy fast.
| Metric | Value |
|---|---|
| First approval | 2022 |
| Clinical AAV programs | Multiple in 2025 |
Preview Before You Purchase
VRIO Analysis
The document you're previewing is the actual uniQure N.V. VRIO Analysis—no mockup or sample—it's a direct snapshot of the exact file you'll receive after purchase, ready to edit and present.
. Diversified CNS gene therapy pipeline
Value
AMT-061/etranacogene dezaparvovec in HOPE-B targets hemophilia B, a rare disease affecting about 1 in 25,000 male births, and Hemgenix launched with a U.S. list price of $3.5 million, showing clear one-time treatment economics. That gives uniQure N.V. a high-value pipeline asset with pricing power and strong orphan-market value.
Rarity
Rarity is high here: only a small group of companies has deep adeno-associated virus (AAV) engineering know-how, and uniQure N.V. has spent more than 10 years building that capability. Its diversified central nervous system pipeline spans multiple gene programs, which is still uncommon in a field where many peers focus on one lead asset.
Imitability
uniQure N.V. has 4 CNS gene therapy programs, and that mix is hard to copy because each asset needs its own vector design, brain delivery path, and long clinical follow-up. The real barrier is execution: rare-disease CNS trials are slow, costly, and biology-heavy, so rivals need years of data, manufacturing know-how, and regulatory skill to match it.
Organization
uniQure N.V. is organized to run a focused CNS pipeline, with a clinical team and regulatory path built around AMT-130 and the approved HEMGENIX asset. Its setup supports parallel trial execution, CMC control, and FDA/EMA planning, which matters because AMT-130 moved into pivotal development in 2025.
Competitive Advantage
uniQure N.V. has a sustained edge because its CNS gene therapy pipeline is hard to copy and backed by patent and CMC know-how, with HEMGENIX already approved and AMT-130 in late-stage Huntington’s disease testing. This mix of one commercial asset and multiple CNS programs makes its claims more enforceable than a single-asset story.
uniQure’s Rare CNS Gene Therapy Pipeline Builds a Durable Moat
uniQure N.V. has 4 CNS gene therapy programs, led by AMT-130 in pivotal Huntington’s disease testing in 2025, and that breadth is rare because each asset needs its own vector design, brain delivery path, and long follow-up. The mix of late-stage CNS work plus an approved asset makes the pipeline harder to copy and supports durable know-how.
| Metric | Data |
|---|---|
| CNS programs | 4 |
| AMT-130 status | Pivotal in 2025 |
| Moat driver | AAV and CMC know-how |
. Rare-disease clinical development and regulatory expertise
Value
AMT-061/etranacogene dezaparvovec in HOPE-B gives uniQure N.V. access to a rare, high-price orphan market: hemophilia B affects about 1 in 25,000 male births, and one-time gene therapy can replace years of chronic factor IX dosing. The clinical data showed durable bleed control, which supports premium pricing and strong payer interest.
Rarity
Rarity is a real moat for uniQure N.V. Only a small set of firms can design adeno-associated virus (AAV) vectors and run rare-disease trials that satisfy regulators. That scarce know-how matters: uniQure already has an FDA- and EU-approved gene therapy in HEMGENIX, which is rare proof that its AAV and regulatory playbook can clear review.
Imitability
Imitability is low: uniQure’s rare-disease edge comes from hard-to-copy AAV delivery, disease biology know-how, and slow clinical execution. In 2025, its AMT-130 Huntington’s program had 36-month data from 29 treated patients, showing this expertise takes years and many patients to build, so rivals cannot quickly match it.
Organization
uniQure N.V. appears built for rare-disease work: it runs a focused clinical pipeline with AMT-130 in Huntington’s disease and AMT-260 in refractory temporal lobe epilepsy, so its teams are set up around small, complex trials and regulator-facing planning. That organization helps it capture value from its gene-therapy know-how, not just invent it.
Competitive Advantage
uniQure N.V.'s rare-disease know-how is hard to copy because it has spent years running gene-therapy trials and working through FDA and EMA paths for small-patient programs. That matters in a field where a single pivotal study can enroll under 50 patients, so its trial design, CMC, and filing playbook can support a sustained, enforceable edge.
uniQure's Rare-Disease Execution Moat Is Hard to Match
uniQure N.V. has a real moat in rare-disease clinical execution: it has already won FDA and EU approval for HEMGENIX, and its AMT-130 program showed 36-month data in 29 Huntington’s patients in 2025. That mix of AAV vector skill, small-trial design, and regulator-facing know-how is hard to copy.
| Key proof | Data |
|---|---|
| HEMGENIX | FDA and EU approved |
| AMT-130 | 29 patients, 36-month data |
. Intellectual property portfolio
Value
AMT-061/etranacogene dezaparvovec is valuable because HOPE-B aimed at hemophilia B, a rare disorder affecting about 1 in 25,000 male births, where a one-time gene therapy can replace years of factor IX use. Hemgenix was launched at a US list price of $3.5 million, showing the market can support very high pricing for durable benefit.
Rarity
uniQure N.V.’s intellectual property is rare because only a small group of firms can engineer adeno-associated virus (AAV) capsids at this depth. That makes its portfolio hard to copy and helps protect a capability built over more than 20 years of AAV gene therapy work.
Imitability
uniQure N.V.’s intellectual property is hard to imitate because adeno-associated virus delivery, payload design, and clinical scaling all take years to refine; that barrier is real in a field where one late-stage gene therapy program can cost hundreds of millions of dollars and still fail. Its lead Huntington’s disease program, AMT-130, underscores the edge: the company’s know-how sits in the vector, the biology, and the trial execution, not just the patent set.
Organization
uniQure N.V. is organized around specialized clinical, CMC, and regulatory teams, which fits a gene-therapy business that depends on trial design, vector manufacturing, and agency filings. Its structure supports focused execution across programs like AMT-130 and hemophilia assets, so the organization itself adds real value by reducing coordination risk and speeding decision-making.
Competitive Advantage
uniQure N.V.’s intellectual property portfolio can support a sustained competitive advantage when its patents, know-how, and process claims are legally enforceable. In gene therapy, enforceable IP matters because development is slow and costly, and even one strong moat can protect a multi-year commercial window around a lead asset like AMT-130.
uniQure’s 20-Year AAV Moat Powers Billion-Dollar Gene Therapy
uniQure N.V.’s IP portfolio is valuable because it protects long-built AAV gene-therapy know-how, rare in a field where one approved therapy can carry a $3.5 million list price and years of R&D. It is hard to copy because the moat sits in patents, vector design, and manufacturing know-how built over 20+ years.
| Metric | Data |
|---|---|
| Hemgenix list price | $3.5 million |
| AAV know-how depth | 20+ years |
| Hemophilia B incidence | 1 in 25,000 male births |
. Specialized manufacturing and quality systems for viral vectors
Value
AMT-061, now etranacogene dezaparvovec, proved Value in HOPE-B by targeting severe hemophilia B, a rare orphan market of about 40,000 patients worldwide, where one-time gene therapy can replace lifelong factor IX infusions. Its US list price was $3.5 million, so uniQure’s specialized viral-vector manufacturing supports premium, high-margin economics if it can scale reliably.
Rarity
Rarity is high: only a small set of firms have deep AAV engineering and GMP manufacturing know-how, and uniQure N.V. has spent more than 20 years building that stack. That kind of process control, analytics, and release testing is hard to copy, so the capability stays scarce and supports its VRIO edge.
Imitability
Imitability is low for uniQure N.V. because AAV delivery, cell biology, and GMP quality controls are hard to copy and take years to build. With 1 approved gene therapy asset and late-stage programs still moving through clinic and manufacturing scale-up in 2025, the know-how sits in process detail, not just equipment.
Organization
uniQure N.V. is organized around specialized clinical operations and regulatory planning, which supports its viral vector manufacturing and quality systems. That structure matters because its lead program AMT-130 entered 2025 with ongoing Phase I/II data generation and FDA/EMA-focused development work, so the organization is built to keep process control tight and filings on track.
Competitive Advantage
uniQure N.V.'s in-house AAV manufacturing and GMP quality systems are a real moat because they combine process know-how, validated release testing, and tight batch control that rivals cannot copy fast. That supports sustained competitive advantage when paired with enforceable patents and trade secrets around vector design and production.
uniQure’s AAV Manufacturing Edge Fuels Its $3.5M Gene Therapy Moat
uniQure N.V.'s in-house AAV manufacturing and GMP quality systems are a hard-to-copy moat because they combine vector engineering, release testing, and batch control. In 2025, that mattered for etranacogene dezaparvovec, priced at $3.5 million in the US, and for AMT-130 scale-up work. The edge is valuable only if batch consistency stays high.
| Metric | Data |
|---|---|
| Lead approved therapy | etranacogene dezaparvovec |
| US list price | $3.5 million |
| Key 2025 focus | AMT-130 manufacturing and filing work |
| Moat source | AAV process control and GMP quality |
. Scientific talent and translational know-how
Value
uniQure N.V.’s scientific talent and translational know-how is valuable because AMT-061, now etranacogene dezaparvovec, targets hemophilia B, a rare orphan market with about 1 in 25,000 male births affected. In HOPE-B, one infusion lifted mean factor IX activity to 37.2% at 24 months, supporting one-time therapy economics in a market where Hemgenix launched at $3.5 million per patient.
Rarity
uniQure’s scientific talent is rare because only a small group of companies has deep adeno-associated virus AAV engineering know-how plus translational experience. That scarcity matters: uniQure reported 2025 R&D spending of about $100 million, showing how much specialized capital and expertise it takes to build and keep this capability.
Imitability
uniQure N.V.’s scientific talent and translational know-how are hard to copy because gene delivery, AAV biology, and trial execution all take years to build. In 2025, its AMT-130 program showed why this matters: only a team that can move from vector design to human data can turn complex science into a clinic-ready asset.
Organization
uniQure N.V. appears organized around specialized clinical, CMC, and regulatory teams, which fits a gene-therapy model that needs tight trial execution and FDA/EMA planning. At year-end 2024, it reported $275.8 million in cash and cash equivalents, helping fund this translational setup.
Competitive Advantage
uniQure N.V. has a real moat in AAV gene-therapy science and moving lab work into clinic, with AMT-130 showing 36-month durable signals in 2025 data that are hard to copy. If its patent and process claims hold up, that know-how can be an enforceable sustained advantage, especially in a field where one clean manufacturing run can make or break value.
uniQure’s $100M R&D Engine Powers AMT-130’s 36-Month Milestone
uniQure N.V.’s scientific talent and translational know-how stayed strategic in 2025, with $100 million in R&D spend backing a narrow AAV gene-therapy skill set. That base helped support AMT-130’s 36-month durability data and the move from vector design to clinic.
| Metric | 2025 |
|---|---|
| R&D spend | $100 million |
| AMT-130 data | 36-month durability |
| Cash and cash equivalents | $275.8 million |
. Partnering, KOL, and patient-center ecosystem
Value
AMT-061/etranacogene dezaparvovec in HOPE-B supports Value because it targets severe hemophilia B, a rare orphan market with 54 treated men in the phase 3 study and durable factor IX expression after one infusion. At a U.S. list price of $3.5 million for HEMGENIX, the one-time therapy model gives uniQure N.V. a high-price, high-need niche with strong payer and KOL relevance.
Rarity
Rarity is high here: only a small set of firms have deep AAV engineering, capsid design, and manufacturing know-how, and uniQure N.V. has built that edge through years of partnering with KOLs and patient groups. That kind of network is hard to copy, because it depends on scarce technical expertise, long clinical ties, and trust built across programs like hemophilia and CNS gene therapy.
Imitability
Imitability is low because uniQure N.V. N.V. must combine AAV delivery, gene-therapy biology, and rare-disease trial execution, and each layer takes years to build and validate. Its partner/KOL and patient-network model is also hard to copy quickly, since in 2025 only a small number of expert centers can run these studies with the needed precision.
Organization
uniQure N.V. looks organized for specialized clinical work: its 2025 focus stayed on AMT-130 and other gene therapy programs, with a structure built around regulatory, medical, and trial execution teams. That setup supports KOL outreach and patient-centered enrollment, which is critical in rare-disease studies with small patient pools and long follow-up windows.
Competitive Advantage
uniQure N.V.’s KOL network, patient ties, and trial-site relationships around AMT-130 form a hard-to-copy ecosystem; once trust, data access, and know-how are built, rivals face higher switching and replication costs. That can support a sustained competitive advantage when licensing terms, data rights, and collaboration claims are enforceable.
uniQure’s KOL-Driven Edge Accelerates Rare-Disease Trial Enrollment
uniQure N.V. uses KOL and patient-center ties to lower trial friction in rare-disease gene therapy, where trust and site access are hard to build. In 2025, its AMT-130 Huntington’s program advanced with ongoing clinical follow-up, and the company ended 2025 with $217.4 million in cash and cash equivalents, supporting partner-led execution.
| Metric | Data |
|---|---|
| Cash and cash equivalents, 2025 | $217.4 million |
| Lead ecosystem | KOLs, patients, expert sites |
| Core use case | Rare-disease trial enrollment |
. Focused operating model and capital discipline
Value
AMT-061/etranacogene dezaparvovec in HOPE-B is valuable because hemophilia B is a rare orphan market, and Hemgenix launched at a US$3.5 million list price for one infusion. That one-time model can replace years of FIX prophylaxis, so uniQure can support premium pricing while keeping capital use focused.
Rarity
uniQure N.V. has a rare edge here because deep adeno-associated virus AAV engineering know-how sits with only a small set of firms. That scarcity keeps its focused operating model lean and lets it protect capital, since few rivals can match the same vector design and development depth.
Imitability
uniQure N.V.’s model is hard to imitate because gene-therapy delivery, vector design, and clinical execution take years to build and are tightly linked to manufacturing know-how. The Company Name also keeps capital tight: in its FY2025 filings, it reported enough liquidity to fund near-term programs, but matching that mix of biology, process control, and trial speed still takes time and money.
Organization
uniQure N.V. runs a lean, specialized model built around clinical ops and regulatory planning, so capital goes mainly to AMT-130 and other pipeline milestones instead of a heavy fixed-cost base. In 2025, that focus helped keep spend tied to trial execution and FDA readiness rather than broad infrastructure.
Competitive Advantage
uniQure N.V.’s edge is not a low-cost operating machine; it comes from a narrow, patent-backed gene therapy platform and clinical know-how, so any advantage is only enforceable while its IP and trial data hold. With R&D-heavy biotechs like uniQure, capital discipline matters because the moat is tied to milestone spending, not scale economics.
uniQure’s Lean Bets on AMT-130 to Drive FY2025 Value
uniQure N.V. keeps a focused operating model by directing most capital to AMT-130 and other pipeline milestones, not to a broad fixed-cost base. In FY2025, that discipline mattered because gene therapy value comes from timed clinical and regulatory execution, not scale.
The Company Name’s lean setup also helps preserve liquidity for the next data readouts and FDA work. Its edge is still tied to narrow, patent-backed know-how, so capital efficiency only pays off if the program keeps moving.
| FY2025 focus | Why it matters |
|---|---|
| AMT-130 | Main capital sink |
| Lean structure | Lower fixed-cost drag |
| Regulatory spend | Funds near-term value |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.